41 results about "Fat mouse" patented technology

The invention discloses application of phlebopus portentosus polysaccharide in preparation of medicines or foods for regulating intestinal flora, reducing blood fat and reducing weight, and belongs to the technical field of biological medicines. The research on the effect of the phlebopus portentosus polysaccharide on obese model mice finds that the polysaccharide can reduce the occurrence of cardiovascular diseases such as atherosclerosis and the like, and has the effect of protecting the liver from being damaged. In addition, the liver injury state of the obese mouse is obviously relieved, the content of total short-chain fatty acid (SCFAs) of the obese mouse is increased, the species diversity of intestinal flora of the mouse is adjusted to a certain extent, and the colony composition is optimized.

The invention discloses application of a lucid ganoderma extract combined with clostridium butyricum in preparation of fat-reducing food or medicine. The invention finds that the ganoderma lucidum extract is combined with clostridium butyricum for use, so that the weight gain of a mouse induced by high-fat diet can be obviously slowed down, the epididymal fat weight of the high-fat mouse is reduced, and the lipid accumulation in the liver and serum of the mouse is reduced; according to the present invention, with the application of the polypeptide, the fat cell size is reduced, the expression of the key gene mRNA related to lipid metabolism and synthesis in the mouse liver is reduced, the intestinal flora of the mouse is regulated, the obesity can be well improved, and the important application prospect in the preparation of the drugs or food for treating diabetes, reducing blood fat, obesity and non-alcoholic fatty liver disease is provided.

Mouse models of obesity associated with human MC4R missense mutations are provided. Human mutations introduced with CRISPR / Cas9 into the mouse MC4R gene lead to an severely obese mouse phenotype in mice with a heterozygous genotype.

The application discloses a norchizhiol triterpenoid compound, a preparation method and application thereof. The norchizhiol triterpenoid compound norchizhiol A can be quickly prepared from Ganoderma lucidum. The test proves that the norchizhiol A can inhibit the accumulation of triglyceride in the differentiation process of 3T3L1 preadipocytes. The norchizhiol A can also effectively reduce the weight increase and liver coefficient of high-fat-diet-induced obese mice, regulate the blood lipid level of the obese mice, and significantly intervene and improve the lipoprotein distribution of the body. The compound can be used for preparing anti-obesity and lipid-lowering medicines.

This invention discloses a strain of *Lactobacillus warfarinii* Z40 and its applications. The taxonomic name of *Lactobacillus warfarinii* Z40 is... Limosilactobacillus walteri Z40, deposited on May 18, 2026 at the China Center for Type Culture Collection (CCTCC), accession number CCTCC NO: M 20261007. This invention isolates a strain of *Lactobacillus warfarinii* Z40 from the intestines of healthy children. It exhibits certain resistance to gastric acid and high bile salts in intestinal fluid, and is non-hemolytic. Mouse model experiments have verified that it can effectively reduce the body weight of obese mice, decrease visceral fat accumulation, lower blood lipid levels, improve abnormal glucose metabolism in mice, and significantly reduce intestinal permeability, thereby improving abnormal phenotypes in mice in multiple ways. It can be applied to products related to weight loss, lowering blood lipids, lowering blood sugar, and improving intestinal barrier function.

The invention relates to the technical field of traditional Chinese medicine extracts, in particular to an application of a ligusticum wallichii alcohol extract and an active monomer thereof in preparation of a product for relieving or treating food-borne obesity. Experimental research finds that when the ligusticum wallichii alcohol extract is singly used, the mRNA expression level of POMC in hypothalamus of a high-fat diet induced food-borne obesity mouse can be reduced, the alpha-MSH level in the hypothalamus can be improved, appetite can be effectively inhibited, body weight can be reduced, meanwhile, the number of lipid droplets in the liver can be reduced, and the ligusticum wallichii alcohol extract has the effects of relieving and treating food-borne obesity, preventing and treating hyperlipidemia and the like. And the application potential of liver tissues is improved, and a new direction and theoretical support are provided for treating food-borne obesity and expanding the medication range of ligusticum wallichii.

The invention belongs to the technical field of biological medicines, and particularly relates to a composite active polypeptide composition with a weight losing effect and a preparation method thereof. The composite active polypeptide composition comprises NT analogue polypeptide ELP3, mulberry leaf polypeptide, balsam pear polypeptide, sea cucumber polypeptide and oyster peptide; the amino acid sequence of the NT analogue polypeptide ELP3 is as shown in SEQ ID NO. 1. According to the present invention, the artificial peptide fragment AYYKSQWLVNGEGTP is added to the end of the wild type NT, such that the gastric acid secretion can be inhibited, and the activity of the alpha-amylase can be significantly inhibited; the NT analogue polypeptide ELP3 and various polypeptide components are matched to achieve a synergistic effect, so that the blood fat metabolism condition of obese mice can be effectively improved, and the fat weight of the mice is reduced; meanwhile, the food intake of the mice can be remarkably inhibited, so that the purpose of reducing the weight of the mice is achieved, and a good weight-losing effect is achieved.

The present invention relates to a preparation method of an exocrine protein Pc and its application in regulating intestinal flora. The fungal-derived Pc protein directly interacts with a protein in the intestinal microorganisms that has exocrine properties and contains a β-N-acetylglucosaminidase (GL) domain and inhibits its enzymatic activity, thereby regulating the proliferation of beneficial microorganisms by alleviating cellular iron and ROS pressure. The Pc protein can regulate the expression of bifunctional autolysins, and can enrich beneficial Staphylococcus bacteria with bifunctional autolysins in the insect intestine, or can enrich beneficial Lachnospiraceae bacteria with bifunctional autolysins in the intestines of healthy mammalian mice, or can enrich Blautia bacteria in the intestines of obese mice induced by a high-fat diet, or can enrich Akkermansia bacteria in the intestines of mice with DSS-induced colitis. The Pc protein can significantly reduce the formation of biofilms of Staphylococcus aureus (S. aureus) with bifunctional autolysins. Pc protein can be used as a new potential prebiotic to regulate the proliferation of beneficial intestinal microorganisms with bifunctional autolysins, and has potential application value in the preparation of food, medicine and disease treatment.

This invention belongs to the field of pharmaceutical technology, specifically relating to the use of a 4-(4-diethylamino-1-methylbutanamino)-7-chloroquinoline derivative or its pharmaceutically acceptable salt, or its tautomer, meso compound, racemic compound, enantiomer, diastereomer, or pharmaceutical composition thereof as an active ingredient in the preparation of drugs for the prevention or treatment of obesity and obesity-related metabolic diseases. The 4-(4-diethylamino-1-methylbutanamino)-7-chloroquinoline derivative of this invention has significant therapeutic effects on obesity and related metabolic diseases. In obese mice induced by a high-fat diet and high-fructose water intake, gavage administration for 6 weeks showed that, compared with the high-fat control group, it inhibited more than 70% of the mice's weight gain, with no significant difference in food intake and water intake, demonstrating good clinical application prospects.

This invention discloses the application of a high-N-acetylglycine-producing *Lactobacillus reuteri* strain in alleviating obesity-related metabolic diseases, belonging to the field of microbial technology. The *Lactobacillus reuteri* NO1 strain of this invention (…) Limosilactobacillus reuteri (NO1) possesses the ability to produce N-acetylglycine in vitro. This strain can inhibit weight gain in obese mice without affecting food intake; improve glucose tolerance in obese mice while reducing blood glucose, serum insulin, and insulin resistance index; regulate liver triglycerides in obese mice, and alleviate liver tissue damage. The *Lactobacillus reuteri* strain described in this invention has very broad application prospects for preparing anti-obesity pharmaceutical compositions and fermented foods.

The application discloses ecdysterone-low molecular weight fructan composite microspheres with fat-reducing and muscle-increasing functions, and a preparation method and application thereof, and belongs to the technical field of biological medicine and functional food. The composite microspheres have a core-shell structure, the inner core is a calcium alginate gel, the outer shell is chitosan, the inner core co-encapsulates ecdysterone and low molecular weight fructan, and the mass ratio of the two is 0.8-1.2:1. The preparation adopts a liquid drop microfluidic technology combined with an internal gelation method to form the inner core, and adopts a post-crosslinking method to coat the outer shell. The composite microspheres are regular in shape, uniform in particle size, high in encapsulation rate, good in stability, excellent in pH response slow-release and anti-degradation characteristics in the gastrointestinal tract. In-vivo pharmacological experiments prove that the composite microspheres can reduce the body weight and body fat rate of obese mice, increase the lean meat content and muscle strength, realize synergistic effects of fat reduction and muscle increase, and can be used for preparing drugs or functional food for improving obesity-related muscle loss, low-muscle obesity and related metabolic syndrome.

The present application relates to the technical field of central obesity related research and treatment, by constructing a central obesity mouse model, it is found that the up-regulation of brain-derived neurotrophic factor (BDNF) expression in adipose tissue is closely related to central obesity resistance. A BDNF fusion polypeptide composed of TAT cell-penetrating peptide, flexible linker and BDNF mature peptide is designed and prepared, the fusion polypeptide has strong cell viability promoting effect at the cellular level, can effectively activate the BDNF signaling pathway and has better stability than natural BDNF protein; an anti-TrkB monoclonal antibody with high affinity and high titer is also prepared. In vivo experiments show that the BDNF fusion polypeptide and its combination with the anti-TrkB monoclonal antibody can effectively inhibit the weight gain of central obesity mice, improve glucose metabolism disorder, increase serum BDNF level and activate the TrkB signaling pathway, and the combination has better synergistic therapeutic effect, which provides a new direction and experimental basis for the treatment of central obesity.

The invention belongs to the technical field of microorganisms, and particularly relates to a strain of Caribik Meyer yeast and application thereof. The strain is isolated from natural plant enzymes. In an in-vitro test, the strain has relatively high TG (Triglyceride) degradation capacity and T-CHO (T-CHO) degradation capacity; in an in-vivo test, the enzyme prepared by fermenting a seed solution of the strain can effectively reduce the weight, fat coefficient and blood fat level of obese mice and relieve pathological changes of fatty liver, has no obvious toxic or side effect, and can be used as a candidate for replacing weight-reducing medicines, so that the enzyme has good practical application value.

The invention relates to the technical field of central obesity related research and treatment, and discovers that up-regulation of brain-derived neurotrophic factor (BDNF) expression in adipose tissue is closely related to central obesity resistance by constructing a central obesity mouse model. A BDNF fusion polypeptide composed of a TAT cell-penetrating peptide, a flexible connecting peptide and a BDNF mature peptide is designed and prepared, and the fusion polypeptide has a strong cell activity promoting effect at a cellular level, can effectively activate a BDNF signal channel and has stability superior to that of natural BDNF protein; the invention also discloses an anti-TrkB monoclonal antibody with high affinity and high titer. In-vivo experiments show that the BDNF fusion polypeptide and the composition of the BDNF fusion polypeptide and the anti-TrkB monoclonal antibody can effectively inhibit weight gain of central obesity mice, improve glucose metabolism disorder, increase serum BDNF level and activate a TrkB signal channel, the synergistic treatment effect of the composition is better, and a new direction and an experimental basis are provided for treatment of central obesity.

The invention belongs to the field of biological medicine, and particularly relates to a construction method and application of a spontaneous obesity model of a systemic GPX3 knock-gene mouse. The construction method comprises the following steps: preparing a precisely targeted GPX3 gene, knocking out a gene editing tool mixture of a specific segment (SEQ ID NO.1) of the GPX3 gene, transferring the gene editing tool mixture into a fertilized egg, and mating a mouse until a stably inherited GPX3 gene knockout homozygous mouse is obtained. The GPX3 is knocked out through the CRISPR / Cas9 technology, the spontaneous obese mouse model which cannot be achieved in the prior art is successfully obtained, the model can simulate obesity-related multi-organ lesions and diabetes mellitus progress, and a reliable tool is provided for obesity mechanism research and drug research and development.

The application discloses a method for relieving obesity cardiomyopathy lipid toxicity by Chemerin and belongs to the technical field of pharmacological research. Mice are selected to establish an obesity mouse model, and are equally divided into a control group, a high-fat diet group, an AAV CMKLR1 virus group, and a high-fat + AAV CMKLR1 virus group. In succession, mouse heart ultrasound, TSE system detection, glucose tolerance test, and insulin tolerance test are carried out, and mouse blood glucose is measured at intervals. Then, tissue protein is extracted for protein immunoblotting, and tissue RNA is extracted for reverse transcription, and then qPCR is used to detect the expression of related genes. After paraffin embedding and slicing of mouse tissues, HE, WGA, immunofluorescence and other pathological staining are carried out. MTBE method is used for lipid extraction and detection of lipid content. ELISA method is used to measure serum Chemerin, and Acyl-RAC method is used to detect protein palmitoylation. Finally, the experimental results are analyzed to draw a conclusion. The present application proves by clinical data and mouse models that Chemerin compensatorily increases in the process of obesity, and Chemerin can relieve cardiac lipid toxicity caused by obesity and protect cardiac function.

The use of an RINL gene and an antagonist thereof in the treatment of obesity. Specifically provided is the use of an RINL gene or an encoded protein thereof. The RINL gene or the encoded protein thereof is used for one of the following: (1) as a marker for diagnosing, detecting or prognosing obesity; (2) in the preparation of a reagent or kit for diagnosing or detecting obesity; or (3) in the preparation of a drug for treating obesity. RINL-KO significantly improves glucose tolerance and insulin resistance of obese mice, ameliorates the accumulation of subcutaneous fat and visceral fat thereof, alleviates the inflammation of adipose tissue thereof, and greatly improves the health of the mice. Therefore, an RINL antagonist has the potential to efficiently treat obesity. It is proposed for the first time that RINL is used as a new target in the preparation of a drug for treating obesity, which is of great significance for new drug screening, and also provides a new idea for the treatment of obesity.

The application relates to the field of biological medicine, and discloses an application of pachyman-derived extracellular vesicles and high-abundance miRNA thereof in relieving obesity. Cell experiments and animal experiments find that the pachyman-derived extracellular vesicles and high-abundance miRNA thereof can up-regulate the expression amount of key genes for brownification of white fat in 3T3-L1 adipocytes and mice in vivo, significantly improve glucose tolerance and insulin resistance of obese mice, and obviously relieve liver steatosis and lipid accumulation. Not only can the pachyman-derived extracellular vesicles and high-abundance miRNA thereof improve obesity from a phenotype, but also can regulate lipid metabolism, and have the value of being applied to preparation of medicines for preventing or relieving obesity and related metabolic complications.

The invention discloses an application of premna microphylla pectin in preparation of a product for preventing and improving diet-induced obesity. The premna pubescens pectin is prepared from premna pubescens leaves as a raw material through extraction, purification and other processes. According to the present invention, the research on the high fat diet induced obese mouse model finds that the body lipid metabolism is regulated by remodeling the intestinal flora structure, particularly reducing the ratio of the phylum firmicutes to the phylum bacteroides, and specifically enriching the beneficial flora such as Muribacaceae and the like by using the premna microphylla pectin; experimental results prove that the premna microphylla pectin can significantly inhibit pathological hypertrophy of adipocytes, reduce visceral fat accumulation, effectively control weight gain and improve dyslipidemia and liver fatty degeneration, and has good biological safety.

The present application relates to a kaurane diterpenoid compound D-33 extracted and separated from the roots of Euphorbia griffithii Hook., a preparation method and uses thereof. Bioactivity tests show that the compound D-33 has a significant weight loss effect in a high-fat diet-induced obese mouse model, can effectively activate uncoupling protein 1 (UCP1) in vitro, and can be used for preparing a thermogenic anti-obesity drug.

The embodiment of the invention provides an effect evaluation system for preventing and treating obesity, and relates to the technical field of analysis. The system comprises a feeding device used for containing multiple groups of obese mouse models, and the multiple groups of obese mouse models comprise experimental group mice, normal group mice and model group mice; the collecting device is used for collecting the liver tissues of the multiple groups of obese mouse models fed for the preset duration; wherein the mice in the experimental group are fed with to-be-experimented articles and high-fat feed, the mice in the model group are fed with high-fat feed, and the mice in the normal group are fed with normal feed; the measuring device is used for measuring the level of liver inflammatory factors in the liver tissue of each group of obese mouse models, and the liver inflammatory factors comprise at least one of the following items: tumor necrosis factor-alpha, interleukin-6 or interleukin-1beta; and the evaluation device is used for evaluating the obesity prevention and treatment effect of the to-be-experimented article based on the liver inflammatory factor levels of the multiple groups of obese mouse models.

The present invention provides a traditional Chinese medicine compound essential oil of yuxianglan and its application in the preparation of products for preventing and treating obesity, and relates to the technical field of traditional Chinese medicine essential oils. The traditional Chinese medicine compound essential oil is made of turmeric essential oil, cyperus rotundus essential oil and gynostemma pentaphyllum essential oil. The traditional Chinese medicine compound essential oil of yuxianglan provided by the present invention, which is administered by inhalation, can significantly reduce the weight gain of obese mice induced by a high-fat diet and inhibit fat production; it can effectively reduce the levels of triglycerides, cholesterol and HDL in obese mice induced by a high-fat diet, and increase the level of LDL, and has the effect of improving the hyperlipidemia symptoms of obese mice, improving the liver's ability to transport phospholipids and cholesterol, and eliminating cholesterol in peripheral blood vessels, thereby regulating lipid metabolism function; at the same time, the traditional Chinese medicine compound essential oil of yuxianglan provided by the present invention can achieve the effect of repairing the intestinal flora disorder caused by a high-fat diet, and restore the intestinal ecological balance of obese mice. The traditional Chinese medicine compound essential oil of yuxianglan provided by the present invention has great application prospects in the treatment or prevention of obesity-related diseases.

The invention discloses a lipid-lowering and sugar-reducing soft capsule as well as a preparation method and application thereof, and belongs to the field of functional foods. The pomegranate seeds and the purple perilla seeds are uniformly mixed, compound co-extraction oil is obtained through supercritical extraction, and the soft capsules capable of efficiently reducing blood fat and blood sugar are further prepared. Experimental results show that the soft capsule provided by the invention can effectively stabilize the weight of a high-fat mouse, remarkably reduce the fasting blood-glucose, total cholesterol, triglyceride and low-density lipoprotein level of the high-fat mouse and increase the high-density lipoprotein level, and the effect of the soft capsule is superior to that of single pomegranate seed oil or purple perilla seed oil. The soft capsule provided by the invention is from a natural source, has the advantages of being green and safe, and lays a solid foundation for developing health-care foods which are beneficial to maintaining the health levels of blood sugar and blood fat and controlling in-vivo fat; meanwhile, a new raw material is provided for research on blood fat reducing and blood sugar reducing medicines. The method has prominent practical application value and wide application prospect.

The present application relates to a kind of preparation method of corncob polysaccharide and its application as lipid inhibitor.A kind of preparation method of corncob polysaccharide includes the steps of preparing defatted corncob dry powder, alkali extraction crude polysaccharide, enzymatic hydrolysis purification, alcohol precipitation and refining, etc., through defatting, ultrasonic alkali extraction, enzymatic hydrolysis purification, low-temperature alcohol precipitation and freeze-drying etc., realize the efficient preparation of corncob polysaccharide from corncob, improve the comprehensive utilization value of corncob, promote the high-value utilization of bulk agricultural and sideline products;The application of polysaccharide component extracted from corncob as lipid inhibitor is also disclosed, the corncob polysaccharide component of the present application can effectively improve the weight gain and fat deposition of obese mice, providing a new solution for the prevention and treatment of obesity, which can be used as fat substitute or functional food ingredient of low-fat food.

This invention relates to a process for extracting, separating, and refining dietary fiber from bamboo shoots. First, fresh Lei bamboo shoots are peeled, washed, and cut into chunks to obtain block-shaped Lei bamboo shoots. The block-shaped Lei bamboo shoots are then crushed by a crusher to obtain wet granules. The wet granules are then subjected to high-speed double-stage pulping to obtain a pulping liquid. The pulping liquid is then spray-dried to obtain powdered bamboo shoot dietary fiber. The bamboo shoot dietary fiber has an uneven, fluffy structure. The refining process is simple and easy to scale up for industrial production. It can be used as a dietary supplement for mice, exhibiting effects such as weight loss, lowering blood lipids, lowering blood sugar, and lowering cholesterol in high-fat mice. Furthermore, the special high-speed double-stage pulping process significantly increases the surface area of ​​the bamboo shoot dietary fiber, which is beneficial for improving its adsorption properties.

The invention discloses a traditional Chinese medicine active ingredient alisol B for promoting white fat browning and application thereof, and belongs to the technical field of biological medicine. The invention discloses a novel medical application of alisol B in promoting adipocyte and adipose tissue browning so as to improve animal obesity, and reveals that alisol B can up-regulate mRNA and protein expression of browning key genes UCP1, PRDM16 and PGC-1alpha in adipocyte for the first time; meanwhile, mRNA and protein expression of browning key genes in white adipose tissues of groins of obese mice induced by high fat diet can be up-regulated, heat production of the obese mice is promoted, energy consumption of organisms is remarkably increased, adaptive heat production capacity of the organisms is improved, and then adipose tissue browning is achieved to improve obesity of the mice. The alisol B can be used for preparing the medicine for treating the related obesity, and a brand new strategy is provided for treating the obesity and related metabolic diseases.

The present disclosure relates to the field of microbial therapy, and specifically to a product for preventing and / or treating obesity and a metabolic syndrome. The product includes a Lactobacillus acidophilus strain JYLA-126 and a coating solution thereof. A bacterial solution of the L. acidophilus strain JYLA-126 is coated with a bacterial coating solution to better transport the bacterial solution to the intestinal tract to exert therapeutic effects. The L. acidophilus strain JYLA-126 coating solution is used for intragastric treatment of obesity mice induced by high-fat diet. Various indicators show that the L. acidophilus strain JYLA-126 coating solution may effectively regulate intestinal microflora and maintain intestinal health. The coating solution improves liver glucose metabolism, reduces liver oxidative stress, improves liver lipid metabolism, and alleviates a liver inflammation level. This coating solution improves white adipose accumulation and promotes brown adipose thermogenesis, thereby achieving effective treatment of obesity and metabolic syndrome in mice.

This invention discloses the application of non-lactolytic streptococci in the preparation of products for preventing obesity, belonging to the field of animal nutrition and feed science and technology. This invention involves preparing non-lactolytic streptococci CCUG41503 into a concentration of 1×10⁻⁶. 8 When a CFU / mL bacterial suspension was administered via gavage to broilers and obese mice, *Streptococcus non-lactolyticus* CCUG41503 reduced abdominal fat percentage and the diameter and area of ​​adipocytes in broilers, and also reduced the weight of epididymal white fat and the diameter and area of ​​adipocytes in obese mice. This indicates that *Streptococcus non-lactolyticus* CCUG41503 has a fat-reducing effect and is widely applicable across multiple species.

The invention discloses application of aucubin in reducing fat deposition, and belongs to the field of biotechnology and animal husbandry application. The new application refers to application of aucubin in preparation of a composition for reducing fat deposition of non-human mammals. In particular, the composition can be used to induce and establish a standardized low fat deposition animal model or state, preferably a high fat diet induced obese mouse model (intragastric dose of 30 mg / kg body weight per day). In addition, the composition can also be used as a feed additive for non-human mammals. The aucubin is developed into a tool for constructing a standardized metabolism scientific research model for the first time, a brand new application scheme is provided for the aucubin as a safe and effective fat deposition regulating agent in livestock production, and the aucubin has important scientific research and industrial value.

The invention discloses exosome vesicle nano-selenium as well as a preparation method and application thereof, the exosome vesicle nano-selenium is prepared by adopting a lactic acid bacteria strain YKX which is screened out from a selenium-rich area and has a high nano-selenium conversion rate, and the influence of the exosome vesicle nano-selenium on mouse glycolipid metabolism disorder based on intestinal flora is studied; results show that the nano-selenium slows down weight increase and obesity of mice to a certain extent; the content of total cholesterol, total triglyceride and low-density lipoprotein cholesterol in serum of obese mice is reduced, and the content of high-density lipoprotein cholesterol is obviously increased; secondly, the intervention of the nano-selenium slows down the increase of the abundance of the mouse intestinal tract thick-wall mycophylum induced by high diet to a certain extent at the phylum level, improves the abundance of bacteroides and the overall diversity of the intestinal flora of the mouse, and improves the disorder of the intestinal flora; and finally, the nano-selenium intervenes in a metabolite level of intestinal microorganisms, so that the content of short-chain fatty acid is increased.